Baltimore-based Sonavex is developing the EchoSure point-of-care imaging technology for monitoring blood clots. The system consists of an absorbable tissue marker to delineate the surgical site and software to guide positioning and extraction of blood-flow data as well as analyze and quantify flow trends to support early detection. David Narrow is the company's CEO.
Q: Why did you choose to locate in Baltimore?
A: Baltimore represents an underrated geography for medical device companies. The region is home to top-notch hospitals, universities, FDA, NIH, NSF, and numerous supporting organizations like the Technology Development Corp. It is also conveniently located within easy travel distance to [Washington,] DC; Philadelphia; New York; and Boston.
Q: What are the pros and cons of being outside of traditional medtech hubs?
A: The biggest challenge is the underwhelming investor presence with a tolerance for FDA-regulated technologies. However, the proximity to other major cities alleviates this issue a bit.
A major benefit is the ability to attract local talent out of top academic institutions, where employees have the luxury of a relatively low cost of living. There are also countless clinical and technical experts eager to collaborate with early-stage companies on new technologies.
|[image courtesy of SONAVEX]|